Jiangsu Hengrui Medicine Co., Ltd
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
Drug-durg Interaction of SHR3680 With Digoxin, Rosuvastatin Calcium and Metformin Hydrochloride
Phase 1
- Conditions
- Interventions
- First Posted Date
- 2020-11-09
- Last Posted Date
- 2020-11-09
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04621669
- Locations
- 🇨🇳
Affiliated Hospital of Qingdao University, Qingdao, China
Study on the Food Effects of Oral SHR4640 Tablets in Healthy Volunteers
- First Posted Date
- 2020-11-09
- Last Posted Date
- 2020-11-09
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT04620408
A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.
- First Posted Date
- 2020-11-06
- Last Posted Date
- 2021-03-16
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 560
- Registration Number
- NCT04619433
- Locations
- 🇨🇳
Beijing Cancer Hosipital, Beijing, Beijing, China
🇨🇳West China Hospital，Sichuan University, Chengdu, Sichuan, China
🇨🇳Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
A Food Effect Study of FMTN on Healthy Chinese Adult Subjects
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2020-11-05
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04616716
- Locations
- 🇨🇳
Jinan Central Hospital, Jinan, China
Study to Evaluate the Mass Babance and Biotransformation of [14C]SHR6390 in Healthy Adult Male Volunteers
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2021-05-12
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT04616742
- Locations
- 🇨🇳
First affiliated hospital,Soochow University, Suzhou, Jiangsu, China
A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-11-03
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 441
- Registration Number
- NCT04613674
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, China
A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2020-10-27
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT04603833
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Study on the Bioavailability of Three Different Prescription Processes of SHR4640 Tablets in Healthy Volunteers
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04586803
A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2023-05-19
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 107
- Registration Number
- NCT04580498
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
A Rifampin Effect Study of SHR2554 on Healthy Chinese Adult Subjects
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04577885
- Locations
- 🇨🇳
Jiangsu HengRui Medicine Co., Ltd., Shanghai, China
© Copyright 2024. All Rights Reserved by MedPath